2型糖尿病大型临床试验的兴奋与沮丧  

Excitement and frustration on megatrials in type 2 diabetes

作　　者：郭庆畲[1] 

机构地区：[1]云南省第二人民医院干疗科,650021

出　　处：《中国老年保健医学》2009年第5期5-6,8,共3页Chinese Journal of Geriatric Care

摘　　要：流行病学资料提示血糖与心血管事件之间有明确的相关性,然而干预试验的结果却不能令人信服,UKPDS虽然能使心肌梗死危险减少16%,却无统计学意义,在去年曾发表了ACCORD、ADVANCE和VADT三个大型临床试验,尽管对血糖能严格控制却不能显示强化治疗的益处,而且在开始出现的微血管并发症的好处,在干预试验结束时并无改变。Epidemiological analyses have extensively suggested a relationship between glyeaemic control and CV events; however,the results of intervention trial have been less conclusive. The UKPDS reported a 16% reduction in the risk of myocardial infarction,but this reduction was not statistically significant. The results of ACCORD,ADVANCE and VADT were published in the last year. In spite of the achievement and maintenance of strict glycaemic control,no beneficial effect of intensive therapy was apparent in any of these studies. Moreover,the initial benefit in terms of microvascular complication observed at the end of the intervention trial remained unaltered at follow-up.

关 键 词：大型试验 2型糖尿病 糖尿病并发症 低血糖 

分 类 号：R587.1[医药卫生—内分泌]